Fact Source: Financial Supervisory Service DART / 2025-11-13
Disclosure Type: Supply Contract / Single Sales Contract (Amendment)
💡 3-Second Summary
Samsung Biologics has extended its non-disclosure confidentiality period regarding a KRW 588.8B contract manufacturing organization (CMO) agreement signed in 2023 from the end of 2025 to August 1, 2031, following the client’s formal request.
📊 1. [Summary of Key Disclosure Content and Major Figures]
- Contract Name: Contract Manufacturing Agreement (Additional production volume under an existing contract)
- Contract Amount: KRW 588,781,733,375 (Fixed amount of USD 451,277,484 converted using the initial exchange rate of KRW 1,304.70/USD on November 28, 2023)
- Ratio to Recent Sales: 19.62% (Compared to the 2022 consolidated financial statement revenue of KRW 3,001,295,197,683)
- Counterparty: A pharmaceutical company located in Asia (Identified remains confidential due to business secrets)
- Contract Period: August 1, 2019 ~ August 1, 2031 (End Date: 2031-08-01)
- Amendment Item (Disclosure Postponement Period): Before: 2025-12-31 → After: 2031-08-01
- Reason for Amendment: Extension of non-disclosure period at the client’s request
- Other Terms: No down payment or advance payment is included. The final contract end date and total amount may be altered upon mutual agreement. The specific identity of the client is likely to remain sealed until after August 1, 2031.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This filing does not announce a newly secured order, but rather acts as an administrative amendment to a massive manufacturing contract originally disclosed on November 28, 2023. Consequently, it does not bring any immediate or direct changes to the company’s cumulative sales or order backlog fundamental metrics.
The primary point for market participants to register is the extension of the non-disclosure deadline. The market originally anticipated that the identity of this large-scale global client would be revealed after December 31, 2025. However, this amendment pushes that disclosure timeline back by over five years to match the contract expiration date of August 1, 2031. Given that the amendment’s cause is noted as “client’s request,” the underlying partnership appears intact. Nevertheless, investors face a prolonged duration of lack of visibility, meaning a prolonged uncertainty risk. This specific filing does not explain the concrete causes behind any earnings fluctuations.
Ultimately, this disclosure should be viewed as an administrative duration adjustments rather than a market-moving event. Since the underlying value accounts for a significant 19.62% of the company’s 2022 revenue, the potential impact of eventual contract adjustments could occur, requiring investors to focus on long-term supply stability.
📝 Editor’s Comment (by K-STOCK Editor)
As this megaton contract accounted for over 19% of the company’s revenue at the time of its initial disclosure in 2023, many investors had been eagerly awaiting the end of this year to discover the true identity of this major Asian pharmaceutical partner. With this amendment, however, that veil will remain unlifted until 2031. Extending confidentiality clauses is a standard industry practice in the global healthcare sector meant to safeguard a client’s broader commercial strategy, so overblown anxiety is unwarranted. Even so, it remains true that market participants will have to tolerate an extended period of opacity regarding a major asset. Because the contract size and duration may still vary down the line by mutual agreement, investors should track subsequent filings patiently rather than jumping to definitive conclusions.
📢 Disclaimer and Source Information
Source: This content has been newly structured and written based on the official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
